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MYC is one of the main PI3K/AKT targets, thus rearrangements underlying PI3K/AKT 56 activation result in MYC overexpression. Deregulation of the PI3K/AKT pathway plays a 57 pivotal role in T-ALL, being constitutively activated in cases with NOTCH1/FBXW7 (50-58 60%) mutations, PTEN (10-30%) inactivation and PTPN2 (6%) deletions. [1] [2] [3] [4] These 59 observations have identified MYC as a key T-ALL oncogene and an effective therapeutic 60 target. 5 The potential role of MYC activation in initiating T-ALL tumorigenesis has been 61 demonstrated in transgenic zebrafish and mouse models, where the induced over-62 expression of MYC lead to T-ALL development with high penetrance and short latency. 5-8 63 Moreover, in T-ALL murine models, MYC appeared to be critical for leukemia initiation, 64 maintenance and self-renewal, as its suppression, prevents leukemia development. 9-11 65
We have characterized an emerging group of T-ALL with MYC-translocations, identified as 66 a specific subgroup of NOTCH1-independent TAL/LMO positive leukemia, occurring in 67 about 6% of adult and childhood T-ALL. 68
69

Study design and Methods 70
To assess the incidence of MYC-translocations in T-ALL, we investigated 64 adults and 71 132 children (supplemental Data). Combined interphase FISH (CI-FISH) and/or Predictive 72
Analysis of Microarrays 12 classified 80% cases into groups according to distinct genetic 73 features: TAL/LMO (57), HOXA (49), TLX3 (31), TLX1 (16), and NKX2-1 (5), whose 74 distribution into age groups reflected previous studies (supplemental Table 1 
Results and discussion 82
Incidence and type of MYC-translocations. MYC-translocations were detected in 12/196 83 cases of T-ALL (6,1%) and were equally distributed between children and adults (Table 1) . 84
They involved TCR loci in 6 cases and new partners in the other 6. The 8q24 breakpoints 85 clustered within the telomeric region of MYC in all TCR translocations, while in the non-86 TCR translocations the 8q24 breakpoints mapped both telomeric and centromeric to MYC 87 (supplemental Figure 1 ) mirroring non-IGH MYC translocations in B-cell ALL. 13 88
Here non-TCR translocation partners were assessed in 4 cases. CDK6/7q21.2, rearranged 89
in T-ALL with t(5;7)( q35;q21) and TLX3 overexpression, 14 was involved in cases 3 and 4. 90
Hitherto undescribed breakpoints involved 1q32.1, in case 1, within a long intergenic non-91 coding RNA, about 300Kb downstream of PTPRC; and Xq25, in case 7, in a no gene 92 region 5Kb of upstream SH2D1 ( Figure 1A , supplemental Data). Whatever the partner, 93 MYC-translocations resulted in MYC over-expression ( Figure 1B) . Remarkably, common 94 to all cases was MYC relocation close to genes which are transcriptionally active in T-95 lymphocytes (supplemental Figure 2) . 96
In T-ALL, high MYC expression is mainly caused by molecular mechanisms acting at the 97 transcriptional or post-transcriptional level. 15 In this study, we have shown that other 98 genes/regions besides TCR may be involved in MYC-translocations and that the incidence 99 of MYC-translocations in T-ALL is higher than previously reported.
supplemental Table 2) . T-ALL with MYC-translocations clustered within the TAL/LMO 104 category (Pearson Chi-square, p= 0,017) ( Figure 1C ). Complete or partial trisomies of 105 chromosomes 6 (3/12, 25%) (Chi-square, P<0,001) and 7 (3/12, 25%) (Chi-square, 106 P<0,001) were significantly associated with MYC-translocations and occurred together in 107 all cases (2, 7, and 11 of Table 1 ). Other co-occurring abnormalities were CDKN2A/B 108 deletions (CDKN2AB del ) (75%) and PTEN inactivation, resulting from deletion or mutation 109 (PTEN del/mut ) (58%). Similar results were found in the MOLT-16 and SKW-3/KE-37 cell 110 lines with t(8;14)(q24;q11)/TCRAD-MYC. In fact, they both carry SIL-TAL1 and/or LMO2-111 translocations, as primary abnormalities, and CDKN2AB del and PTEN del/mut as additional 112 hits (supplemental Table 3 ). PTEN inactivation in primary samples as well as cell lines 113 reflect results from experimental mouse models, which have shown that Myc 114 rearrangements and Pten del exert a synergistic effect in the development of T-ALL, and 115 appearing to replace the function of Notch1. 8, 16 Interestingly, PTEN del/mut and NOTCH1 116 mutation were mutually exclusive in our cases, confirming that they arise in different T-ALL 117
subgroups. 17 In a unique TLX1 positive case (no.12), the MYC-translocation was 118 associated with PTPN2 loss. The two PTEN and PTPN2 negative regulators of PI3K/AKT 119 signalling, 18 were inactive in approximately 65% of our cases, suggesting that constitutive 120 PI3K/AKT pathway activation is a critical synergistic hit in this T-ALL subgroup. with MYC-translocations increased at relapse, rising from 8% to 100% (Table 1) , whereas 140 other abnormalities, which were present either in the main clone, i.e. ETV6 del , or in diverse 141 subclones, such as WT1 del and BCL11B del , disappeared at relapse ( Figure 1G ). These 142 findings are in line with results from xenograft models 19 which showed that MYC confers a 143 proliferative advantage and resistance to drug toxicity. It is noteworthy that in mice c-Myc 144 plays a crucial role in maintenance and self-renewal of leukemia-initiating cells, which are 145 thought to be resistant to chemotherapy and mediate relapse. 11 In case 11, the MYC-146 translocation, present at relapse, was not detected at diagnosis, implicating that it was 147 acquired during disease progression ( Figure 1G ). Taken together, these data suggest that 148 identification and possible eradication of small MYC-positive subclones at diagnosis and/or 149 during the early stages of treatment may assist in prevention of disease progression. 150
Notably, MYC-translocations were found in subclones of variable size (range: 8-62%) in 4 151 additional cases (Table 1) . 152
Clinical and hematological characteristic of T-ALL with MYC-translocations. MYC-153
translocation positive T-ALL is characterized by leukocytosis and cortical/mature 154 differentiation arrest in the majority of cases. It was not possible to evaluate the prognostic 155 implications of MYC-translocations in this retrospective study including children and adults 156 belonging to different treatment protocols. However, poor prognostic markers, such as 157 high CD44 expression and PTEN inactivation, appeared to be strongly associated with this 158 translocations (nos. 1-4,9,10; Table 1 ) clustered together and separated from the 7 cases 280 without; E) Q4 TAL/LMO positive T-ALL: CD44 expression was higher in T-ALL cases with 281 MYC-translocation compared to cases without; F) NOTCH1 expression was significantly 282 lower in cases with MYC-translocations compared to cases without; G) Longitudinal FISH 283 studies in 2 cases: in case no. 11 the clone with MYC-translocation was not detected at 284 diagnosis but only at relapse (left); in case no.12, the small subclone (~8%) with the MYC-285 translocation present at diagnosis was found in 100% of leukemic blasts at relapse. 286
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